Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro biofilm and in vivo implant infections

Vor, Lisanne de; B, van Dijk; Kessel, van; Kavanaugh, J.S.; Cj, de Haas; Pc, Aerts; Mc, Viveen; Ec, Boel; Ac, Fluit; Kwieciński, Jakub; Gc, Krijger; Rm, Ramakers; Fj, Beekman; Dadachova, Ekaterina; Mg, Lam; Hc, Vogely; Bc, van der Wal; Ja, van Strijp; Horswill, AR; Weinans, Harrie; Sh, Rooijakkers

doi:10.1101/2021.02.09.429966

Cited by 5 publications

(2 citation statements)

References 84 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S. aureus strain wood 46 (ATCC 10832; de Vor et al, 2021 ) and wild-type (WT) GBS clinical isolate NCTC 10/84 (1169-NT1; ATCC 49447; serotype V; Sheen et al, 2011 ) were gifts from Suzan Rooijakkers (UMC, University Medical Center, Utrecht, Netherlands) and Nina van Sorge (AMC, AcademicMedical Center, Amsterdam, Netherlands), respectively. Bacteria were stored at −80°C.…”

Section: Methodsmentioning

confidence: 99%

Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus

et al. 2021

View full text Add to dashboard Cite

The bacterial pathogens Streptococcus agalactiae (GBS) and Staphylococcus aureus (S. aureus) cause serious infections in humans and animals. The emergence of antibiotic-resistant isolates and bacterial biofilm formation entails the urge of novel treatment strategies. Recently, there is a profound scientific interest in the capabilities of non-digestible oligosaccharides as antimicrobial and anti-biofilm agents as well as adjuvants in antibiotic combination therapies. In this study, we investigated the potential of alginate oligosaccharides (AOS) and chitosan oligosaccharides (COS) as alternative for, or in combination with antibiotic treatment. AOS (2–16%) significantly decreased GBS V growth by determining the minimum inhibitory concentration. Both AOS (8 and 16%) and COS (2–16%) were able to prevent biofilm formation by S. aureus wood 46. A checkerboard biofilm formation assay demonstrated a synergistic effect of COS and clindamycin on the S. aureus biofilm formation, while AOS (2 and 4%) were found to sensitize GBS V to trimethoprim. In conclusion, AOS and COS affect the growth of GBS V and S. aureus wood 46 and can function as anti-biofilm agents. The promising effects of AOS and COS in combination with different antibiotics may offer new opportunities to combat antimicrobial resistance.

show abstract

Section: Methodsmentioning

confidence: 99%

Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The antibody disrupted biofilms formed by S. typhimurium and eventually enhanced the efficacy of antibiotic treatment in vivo. In mice, a 3H3 injection showed antibiotic conciliated clearance of S. typhimurium biofilms in catheters [211][212][213][214]. Sun et al used a mixture of two MAbs, 12C6/12A1 and 3C1/12A1, which synergistically reduced the attachment and accumulation of S. epidermidis up to 87% [215].…”

Section: Antibodies and Macrophagesmentioning

confidence: 99%

Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance

et al. 2022

View full text Add to dashboard Cite

A biofilm is a community of stable microorganisms encapsulated in an extracellular matrix produced by themselves. Many types of microorganisms that are found on living hosts or in the environment can form biofilms. These include pathogenic bacteria that can serve as a reservoir for persistent infections, and are culpable for leading to a broad spectrum of chronic illnesses and emergence of antibiotic resistance making them difficult to be treated. The absence of biofilm-targeting antibiotics in the drug discovery pipeline indicates an unmet opportunity for designing new biofilm inhibitors as antimicrobial agents using various strategies and targeting distinct stages of biofilm formation. The strategies available to control biofilm formation include targeting the enzymes and proteins specific to the microorganism and those involved in the adhesion pathways leading to formation of resistant biofilms. This review primarily focuses on the recent strategies and advances responsible for identifying a myriad of antibiofilm agents and their mechanism of biofilm inhibition, including extracellular polymeric substance synthesis inhibitors, adhesion inhibitors, quorum sensing inhibitors, efflux pump inhibitors, and cyclic diguanylate inhibitors. Furthermore, we present the structure–activity relationships (SAR) of these agents, including recently discovered biofilm inhibitors, nature-derived bioactive scaffolds, synthetic small molecules, antimicrobial peptides, bioactive compounds isolated from fungi, non-proteinogenic amino acids and antibiotics. We hope to fuel interest and focus research efforts on the development of agents targeting the uniquely complex, physical and chemical heterogeneous biofilms through a multipronged approach and combinatorial therapeutics for a more effective control and management of biofilms across diseases.

show abstract

Antibodies Against Biofilms: Mechanisms and Applications

Watson

Maan

Kolodkin‐Gal

et al. 2022

Springer Series on Biofilms

View full text Add to dashboard Cite

Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro biofilm and in vivo implant infections

Cited by 5 publications

References 84 publications

Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus

Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus

Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance

Antibodies Against Biofilms: Mechanisms and Applications

Contact Info

Product

Resources

About